ArticleMedicine2026
Association between neutrophil-to-HDL cholesterol ratio and diabetic nephropathy in adults with diabetes mellitus: A cross-sectional study from NHANES 2007-2018.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal complications in diabetes impose substantial morbidity globally, yet early risk stratification remains challenging. The neutrophil-to-HDL cholesterol ratio (NHR) represents an integrated biomarker reflecting both immune activation and dyslipidemia, with neutrophilia promoting renal inflammation and low HDL-C impairing renoprotective mechanisms. We evaluated whether NHR is associated with diabetic nephropathy (DN) in a population-based cross-sectional study. We analyzed 2005 diabetic adults from six NHANES cycles (2007-2018). DN was defined as microalbuminuria (UACR ≥ 30 mg/g) or reduced eGFR (<60 mL/min/1.73m2) calculated via CKD-EPI 2021. NHR was computed as the ratio of neutrophil count to HDL-C concentration. Multivariable logistic regression with sequential covariate adjustment (demographics, socioeconomic factors, and comorbidities) was used to examine NHR-DN associations. Quartile-based dose-response analysis and restricted cubic spline modeling were additionally performed to characterize the association shape. DN prevalence reached 37.31% (n = 748). Individuals with nephropathy exhibited 15% higher median NHR (3.691 vs. 3.211, P < .001). Fully adjusted models revealed that per-unit NHR elevation increased DN odds by 22.48% (OR 1.2248, 95%CI 1.1533-1.3017, P < .001). Quartile analysis demonstrated dose-response relationships: top quartile participants showed 2.70-fold higher nephropathy risk versus bottom quartile (OR 2.6967, 95%CI 1.9965-3.6556, p-trend < 0.001). Higher NHR independently correlates with diabetic nephropathy presence in US adults. This readily calculated index combining inflammatory and metabolic dimensions may enhance clinical risk assessment. These observational findings suggest that NHR may serve as a complementary marker to support kidney disease risk stratification in diabetic patients, pending confirmation by prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.